Addressing Challenges in Inhaled Antifungal Drug Development —
September 25, 2020

Speakers and Panelists: Affiliations and Disclosures

Barbara D. Alexander, MD, MHS
President-Elect, Infectious Diseases Society of America (IDSA)
Director, Transplant Infectious Diseases (ID) Service
Director, Transplant ID Fellowship Program
Head, Clinical Mycology Laboratory
Professor of Medicine and Pathology
Duke University School of Medicine
Durham, NC

David Andes, MD
William A Craig Professor
Head, Division of Infectious Diseases
Director, Wisconsin Antimicrobial Discovery and Development Center
Departments of Medicine, Microbiology, and Immunology
University of Wisconsin
Madison, WI

Darius Armstrong-James, BM, MSc, PhD, FRCP
Reader, Infectious Diseases and Medical Mycology
Department of Infectious Diseases
Imperial College London
London, UK

Shukal Bala, PhD
Microbiologist
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, FDA

Rohit Bazaz, PhD
Honorary Senior Clinical Lecturer
University of Manchester
Consultant in Infectious Diseases, National Aspergillosis Centre
Manchester, UK

Timothy Bensman, PharmD, PhD
Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS), CDER, FDA
Silver Spring, MD
Lance Berman, MBChB, MS
Chief Medical Officer
Pulmocide, Ltd.
London, UK

Malcolm Birrell
Patient Representative, Allergic Bronchopulmonary Aspergillosis
Manchester, UK

Brandon Blakely, PhD
Biomedical Engineer, Acting Team Lead, Respiratory Devices Team
Division of ENT, Sleep, Respiratory, and Anesthesia, Office of Health Technology 1 (OHT1)
Office of Product Evaluation and Quality (OPEQ), CDRH, FDA
Silver Spring, MD

Radu Botgros, MD
Scientific Officer
Office of Biological Health Threats and Vaccines Strategy
European Medicines Agency (EMA)
Amsterdam, The Netherlands

Irene Chan, PharmD
Deputy Director
Division of Medication Error Prevention and Analysis (DMEPA), Office of Medication Error
Prevention and Risk Management
Office of Surveillance and Epidemiology, CDER, FDA
Silver Spring, MD

Dale J. Christensen, Ph.D.
Director of Development
TFF Pharmaceuticals Inc.
Austin, TX

Cornelius (Neil) J. Clancy, MD
Associate Chief of VA Pittsburgh Health System (VAPHS) and Opportunistic Pathogens
Chief, Infectious Diseases Section, VA Pittsburgh Health Care System
Associate Professor of Medicine
Director, Mycology Program and XDR Pathogen Lab
Department of Medicine, University of Pittsburgh
Pittsburgh, PA
Russell (Rusty) Clayton, DO  
Principal  
Aeremedea LLC  
Pulmatrix, Inc.  
Fenandina Beach, FL

Philip Colangelo, Pharm.D., PhD  
Team Leader, Clinical Pharmacology  
DIDP, OCP  
OTS, CDER, FDA  
Silver Spring, MD

David B. Corry, MD  
Professor, Medicine-Immunology, Allergy and Rheumatology  
Baylor College of Medicine  
Houston, TX

Shampa Das, PhD  
Antimicrobial Pharmacodynamics and Therapeutics  
Department of Pharmacology  
University of Liverpool  
Liverpool, UK

David Denning, FRCP FRCPath FIDSA FMedSci  
Chief Executive, Global Action Fund for Fungal Infections  
Professor of Infectious Diseases in Global Health  
The University of Manchester  
Manchester, UK

Cheryl Dixon, PhD  
Statistical Reviewer  
Division of Biometrics IV (DBIV), Office of Translational Sciences (OTS)  
CDER, FDA  
Silver Spring, MD

Anthony Durmowicz, MD  
Vice President, Clinical Development  
Cystic Fibrosis Foundation  
Bethesda, MD

John Farley, MD, MPH  
Director  
OID  
OND, CDER, FDA  
Silver Spring, MD
Paul A. Greenberger, MD
Professor of Medicine
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, IL

Shahid Husain, MD, MSc
Director of Transplant Infectious Diseases
University Health Network, Toronto General Hospital
Professor of Medicine, University of Toronto
Toronto, Canada

Caroline Jjingo, MD, MPH
Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Charlotte Keywood, MD
Head of Global R&D
Zambon SpA
Milano, Italy

Yongman Kim, PhD
Team Lead, Statistician
DBIII, Office of Biostatistics
OTS, CDER, FDA
Silver Spring, MD

Robert Lim, MD
Team Lead, Medical Officer
Division of Pulmonary, Allergy and Critical Care (DPACC), OII
OND, CDER, FDA
Silver Spring, MD

Kieren Marr, MD, MBA
Professor of Medicine
Vice Chair of Medicine for Innovation in Healthcare Implementation
Director of Transplant and Oncology Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Owen McMaster, PhD
Pharmacology/Toxicology Reviewer
Division of Pharmacology/Toxicology for Infectious Diseases (DPT-ID), OID OND, CDER, FDA
Silver Spring, MD

Richard Moss, MD
Professor Emeritus, Department of Pediatrics
Stanford University School of Medicine
Attending Physician, Lucile Packard Children’s Hospital and Stanford Children’s Health at Stanford University Medical Center
Stanford, CA

Sumati Nambiar, MD, MPH
Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Mark Needles, MD
Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Luis Ostrosky-Zeichner, MD
Vice-Chair of Medicine
Director of the Laboratory of Mycology Research
McGovern Medical School
Houston, TX

John Perfect, MD
Professor of Medicine
James B. Duke Distinguished Professor of Medicine
Chief, Division of Infectious Diseases
Professor in Molecular Genetics and Microbiology
Durham, NC

Khalid Puthawala, MD
Reviewer
DPACC, OII
OND, CDER, FDA
Silver Spring, MD
Edwin Rock, MD, PhD
Chief Medical Officer
Partner Therapeutics
Lexington, MA

Donald Sheppard M.D.
Director, McGill Interdisciplinary Initiative in Infection and Immunity
Chair, Department of Microbiology & Immunology
Professor, Departments of Medicine; Microbiology & Immunology
McGill University

Thomas Smith, MD
Clinical Team Lead
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Christopher St. Clair, PharmD
Reviewer
Division of Clinical Outcome Assessment, Office of Drug Evaluation Sciences
OND, CDER, FDA
Silver Spring, MD

William J. Steinbach, MD
Samuel L. Katz Professor of Pediatrics
Professor in Molecular Genetics and Microbiology
Chief, Pediatric Infectious Diseases
Duke University
Durham, NC

David A Stevens, MD
Professor (Emeritus) of Medicine
Stanford University Medical School
President of the California Institute for Medical Research
San Jose, CA

Thomas Walsh, MD, PhD
Founding Director, Transplantation-Oncology Infectious Diseases Program
Chief, Infectious Diseases Translational Research Laboratory
Professor of Medicine, Pediatrics, and Microbiology & Immunology
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital
Henry Schueler Foundation Scholar
Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation
New York, NY
Peter Wark, MB, PhD
Conjoint Professor
Centre for Healthy Lungs, HMRI.
Department of Respiratory and Sleep Medicine
John Hunter Hospital
New South Wales, Australia

Disclosures

Barbara Alexander has received research grants to Duke University from Lediant, served as site investigator for clinical trials for F2G, Cidara, Scynexis, Amplyx, Ansun and Astellas and as a consultant for Shionogi, Scynexis and Lediant.

David Andes has served as a consult to Amplyx, Cidara, Merck, Roche, sFunga, Matinas, and Scynexis.

Darius Armstrong-James has received grants from Pulmocide Ltd and Gilead. He has received speaker fees from Gilead and AstraZeneca.

Lance Berman is a full-time employee of Pulmocide.

Cornelius Clancy is an employee of the US Department of Veterans Affairs and the University of Pittsburgh. Dr. Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta, and Cidara for studies unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems.

Russell Clayton is an interim executive and consultant for companies developing and commercializing pharmaceutical, biologic, and medical device products. He is currently working with Pulmatrix, Larimar Therapeutics, and Vielight, Inc., and serves on the scientific advisory board of Larimar Therapeutics and DZS Clinical Services.

David Corry is a scientific advisor for and has intellectual property in Atrapos Therapeutics, LLC

Shampa Das is a full time employee of the University of Liverpool. She holds research grants with Spero Therapeutics, Allecra, Antabio, Bugworks, NAEJA-RGM, F2G and Phico. Shampa Das has acted as a consultant for CARB-X, Wellcome Trust, Spero Therapeutics, Centauri Therapeutics and is a member of the EUCAST steering committee.

David Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm. In
the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.

Paul Greenberger is a member of the U.S. Food and Drug Administration’s (FDA, CBER) Allergenic Products Advisory Committee (APAC). He has consulted for Allergy Therapeutics and receives royalties from Up To Date and Wolters Kluwer.

Shahid Husain has received grants from Merck, Pfizer, AVIR and Astellas.

Charlotte Keyword is a full time employee of Zambon SpA

Kieren Marr is founder and CEO of MycoMed Technologies. Consultant and Advisory Board member for Cidara Therapeutics and Sfunga Therapeutics. She has consulted for Amplyx Pharmaceuticals, Astellas Pharma, Advaxis, Chimerix, F2G Ltd, Genentech, Incyte Corp, Merck & Co., OncoSec, RTI Surgical, Scynexis, Inc. and Vical. She receives authorship and editorial royalties from UpToDate and a grant from Merck.

Richard Moss – Dr. Moss is currently a consultant to the Cystic Fibrosis Foundation, Pulmatrix, Mayne Pharma, Zambon Company SpA, Aridis Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, and Proteostasis Therapeutics Inc. He receives authorship and editorial royalties from Up To Date. He is on the Board of Directors of Cystic Fibrosis Research Inc.

Luis Ostrosky-Zeichner has received research funding and/or personal honoraria for consulting or speaking from Pfizer, Merck, Astellas, Cidara, Scynexis, F2G, Amplyx, Gilead, Therapeutics, Inc, Viracor, Octapharma, Biotoscana, Stendhal, Mayne, Takeda, RealTime labs, and Viracor.

John Perfect – John R Perfect is a consultant for Merck, Astellas, F2G, Amplyx, Appili, Minnetronix, Scynexis, and Matinas. He has research grants with Astellas, Appili, Minnetronix, Pfizer and Amplyx.

David A. Stevens has recently acted as a consultant to Riptide, Inc.; and recent research contracts held with Riptide, Inc.; Aridis, Inc.; Valley Fever Solutions, Inc. and Ganga Today Trust, and has received speaker fees from Pfizer China.

Don Sheppard receives grant support from Atara and has served as consultant to Amplyx, AVIR, Merck, Pfizer, and Cidara.

William Steinbach is a consultant to Sfunga and Astellas

Thomas Walsh has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, and Tetraphase and has served as consultant to Amplyx, Astellas,
Allergan, ContraFect, Gilead, Leadiant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.

**Peter Wark** is an employee of New South Wales Health. He has acted as a consultant for Pulmatrix and received honoraria for this. He is a voluntary board member for Cystic Fibrosis Australia and the National Asthma Council (Australia).